Businesshala News, citing sources, reported that GlaxoSmithKline’s consumer healthcare unit is taking buyout interest from private equity firms such as Advent, CVC and KKR.
A venture with Pfizer could also attract some of the world’s largest pharmaceutical and consumer goods companies, the report said on Tuesday, adding the business could be valued at 40 billion pounds ($54 billion) or more. Is.
A GSK spokesperson declined to comment when asked whether the company has received an acquisition interest in the consumer healthcare business.
The London-listed company planned to convert the consumer arm into a separate listed company in June to boost its underperforming drug business, and has strongly defended those plans even after active investor Elliott raised concerns.